Table of Contents Author Guidelines Submit a Manuscript
Journal of Drug Delivery
Volume 2015, Article ID 574247, 9 pages
http://dx.doi.org/10.1155/2015/574247
Research Article

Design and Characterization of Buccoadhesive Liquisolid System of an Antihypertensive Drug

Department of Pharmaceutics & Pharmaceutical Technology, K. B. Institute of Pharmaceutical Education & Research, Sector 23, Gandhinagar, Gujarat 382023, India

Received 16 July 2015; Revised 26 September 2015; Accepted 29 September 2015

Academic Editor: Juan M. Irache

Copyright © 2015 Nilesh P. Kala et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Nifedipine is an antihypertensive BCS class II drug which has poor bioavailability when given orally. The objective of the present study was to increase the bioavailability of nifedipine, by formulation and evaluation of a buccoadhesive liquisolid system using magnesium aluminium silicate (Neusilin) as both carrier and coating material and dissolution media were selected based on the solubility studies. A mixture of carboxymethylcellulose sodium and carbomer was used as mucoadhesive polymers. Buccoadhesive tablets were prepared by direct compression. FTIR studies confirmed no interaction between drug and excipients. XRD studies indicated change/reduction in crystallinity of drug. The powder characteristics were evaluated by different flow parameters to comply with pharmacopoeial specifications. The dissolution studies for liquisolid compacts and tablet formulations were carried out and it was found that nifedipine liquisolid tablets formulated from bioadhesive polymers containing 49% liquisolid system, 17.5% carbomer, and 7.5% carboxymethylcellulose sodium showed the best results in terms of dissolution properties. Prepared formulation batches were evaluated for swelling, bioadhesion strength, ex vivo residence time, and permeability studies. The optimized batch was showing promising features of the system. Formulating nifedipine as a buccoadhesive tablet allows reduction in dose and offers better control over the plasma levels.